Want to see TRDA full AI Analyst Report?
TRDA Stock Chart & Stats
$13.99
-$0.56(-3.25%)
At close: 4:00 PM EST
$13.99
-$0.56(-3.25%)
Day’s Range― - ―
52-Week Range$4.93 - $16.45
Previous CloseN/A
Volume35.15K
Average Volume (3M)331.85K
Market Cap
$267.47M
Enterprise Value$322.86
Total Cash (Recent Filing)$254.86M
Total Debt (Recent Filing)$49.75M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 12, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding38,820,618
10 Day Avg. Volume407,673
30 Day Avg. Volume331,845
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)16.73
P/FCF Ratio-3.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.75Price Target Upside34.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.91
Revenue Forecast (FY)$19.37M
Bulls Say, Bears Say
Bulls Say
Proprietary EEV Delivery Platform & Diversified PipelineEntrada's Endosomal Escape Vehicle (EEV) is a durable, platform-level competitive advantage: enabling intracellular delivery of proteins/peptides expands addressable indications and allows multiple programs to leverage the same technology. Platform breadth reduces single-program binary risk and supports long-term partnership and royalty potential if clinical translation succeeds.
Positive Early Phase 1/2 DMD SignalsStatistically significant functional improvement with benign safety in ENTR-601-44 Cohort 1 materially de-risks that franchise and validates EEV delivery in a clinical neuromuscular setting. Durable implication: improved probability of later-stage success, stronger partner interest, and a clearer path to commercial uptake in a large, underserved DMD market if results hold in larger cohorts.
Manageable Balance Sheet And Near-term RunwayCash and marketable securities providing runway into Q3 2027 give the company time to deliver multiple 2026 data readouts without immediate financing. This reduces short-term refinancing risk, preserves strategic optionality for partnerships or selective spend, and supports continued clinical execution across several programs over the next 12-18 months.
Bears Say
High Operating Cash BurnSustained negative operating and free cash flow of ~-$132M TTM is a durable structural risk: ongoing clinical spend will continue to erode resources and likely require external financing or partnerships. Repeated capital raises dilute existing shareholders and can constrain long-term strategy, making execution-dependent value creation more uncertain.
Sharp Revenue Decline And Earnings VolatilityA ~77% revenue drop and swing to a large net loss indicate reliance on lumpy collaboration revenue and highlight volatile operating leverage. This structural volatility complicates forecasting, increases funding uncertainty, and means long-term value depends heavily on successful clinical and partnership milestones rather than stable product sales.
Expanded Equity Plans Raise Dilution RiskAmendments expanding equity incentive and ESPP capacity improve talent retention but increase potential share issuance over time. Given negative cash flow and likely ongoing funding needs, expanded equity authority creates a durable dilution pathway that can materially affect per-share economics if further financings or equity compensation usages occur.
Entrada Therapeutics Inc News
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $16.45 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Entrada Therapeutics Inc’s market cap is $267.47M.
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.037 by $0.087.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -1.05.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 38,820,618 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.037. Following the earnings report the stock price went down -57.268%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Currently, no hedge funds are holding shares in TRDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entrada Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.75 (34.02% Upside)
$18.75 (34.02% Upside)
Blogger Sentiment
Bullish
TRDA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 52.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $29.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.03%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
TRDA Stock 12 Month Forecast
Average Price Target
$18.75
▲(34.02% Upside)
Technical Analysis
―
Black Diamond Therapeutics
―
C4 Therapeutics
―
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
35.99% Insiders
8.15% Mutual Funds
36.84% Other Institutional Investors
10.67% Public Companies and
Individual Investors